Baird-Sponsored Microwave Ablation Training Enhances Thyroid Treatment Capabilities for Leading Arizona Surgeon

Rhea-AI Summary

Baird Medical (NASDAQ: BDMD) announced completion of an advanced Microwave Ablation (MWA) training session on Dec. 8, 2025 led by Dr. Emad Kandil.

The program trained Dr. Richard Harding of Arizona Endocrine Surgery with observation of three live MWA procedures, a hands-on component, and strategic planning for integrating MWA into his Phoenix practice. Dr. Harding received a Certificate of Completion, underscoring proficiency in MWA and supporting expanded patient access to non‑surgical thyroid treatment options in Arizona.

Key Figures

Live MWA procedures observed 3 procedures New Orleans training session for Dr. Harding

Share price $1.63 Pre-news current price

Daily price change 1.24% Change over prior 24 hours

Today’s volume 336,348 shares Pre-news trading volume

20-day avg volume 153,921 shares Short-term liquidity baseline

Volume multiple 2.19x Today’s volume vs 20-day average

52-week high $12.5025 52-week trading range

52-week low $1.02 52-week trading range

Market Reality Check

$1.40 Last Close

Volume Volume 336,348 is 2.19x the 20-day average, signaling elevated pre-news interest. high

Technical Shares at $1.63 are trading below the 200-day MA of $3.45 and 86.96% below the 52-week high.

Peers on Argus

Peer moves are mixed: ICAD up 3.48%, APYX, ICCM, XTNT down between 1.27–6.1%, and NSPR flat, suggesting BDMD’s action is more stock-specific than sector-driven.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Dec 03	Leadership appointment	Positive	+11.1%	Named seasoned U.S. CEO to lead commercial expansion for MWA platform.
Nov 03	International adoption	Positive	-9.2%	First successful microwave bone ablation marking entry into Egyptian market.
Oct 27	Reimbursement milestone	Positive	+2.1%	New York endocrinology practice reported nine MWA cases reimbursed by Medicare.
Oct 23	International adoption	Positive	-5.9%	First liver tumor MWA procedure in Bangladesh, patient recovering well.
Oct 21	Physician training	Positive	-1.9%	Thyroid MWA workshop in Malaysia to advance minimally invasive skills.

Pattern Detected

Operationally positive adoption and expansion news has produced mixed reactions, with several international milestone updates followed by negative price moves despite constructive clinical and commercial progress.

Recent Company History

Over the last few months, BDMD has focused on international expansion and clinical adoption of its microwave ablation platform. In October–November 2025, it reported first successful liver and bone tumor ablations in Bangladesh and Egypt, Medicare-reimbursed thyroid procedures in New York, and a thyroid MWA workshop in Malaysia. On Dec 3, 2025, it appointed a U.S. CEO to drive commercial entry. The current Arizona-focused training update extends this physician-education and adoption narrative in another U.S. market.

Market Pulse Summary

This announcement highlights Baird Medical’s continued emphasis on physician training, showcasing advanced microwave ablation education for a leading Arizona thyroid surgeon and observation of three live procedures. It extends a recent series of adoption and workshop updates across multiple geographies. Investors tracking BDMD’s story may watch for evidence of increased procedure volumes, additional U.S. practice integrations, and reimbursement developments that translate this training work into durable commercial adoption.

Key Terms

microwave ablation medical

"a market leader in Microwave Ablation (MWA) technology, recently concluded"

Microwave ablation is a medical procedure that uses focused microwave energy to heat and destroy abnormal tissue, such as tumors, through a needle-like probe inserted into the body; think of it as using a tiny, targeted microwave oven to cook away problem cells without large incisions. It matters to investors because it represents a growing category of minimally invasive treatments that can reduce hospital stays, create demand for specialized devices and disposables, and influence reimbursement and adoption trends in healthcare markets.

minimally invasive therapies medical

"commitment to accelerating the adoption of minimally invasive therapies through"

Minimally invasive therapies are medical procedures that treat disease or injury using small cuts, needles, or focused energy instead of large surgical openings, much like fixing a watch through a tiny access point rather than dismantling the whole case. Investors care because these approaches often lower costs, shorten hospital stays, and speed recovery, which can increase procedure volumes, shift care to outpatient settings, and boost demand for specialized devices and technologies.

radiofrequency ablation medical

"first surgeon in Arizona to perform both thyroid Radiofrequency Ablation (RFA)"

A medical procedure that uses a thin probe to deliver controlled heat (radiofrequency energy) to destroy or disable problematic tissue, such as small tumors, overactive nerves, or abnormal heart pathways; think of it as applying a focused heat spot to stop a problem without large incisions. Investors care because the technique drives demand for specialized devices, affects treatment volumes, reimbursement rates, and regulatory approvals, all of which influence medical-device and healthcare company revenues.

transoral endoscopic thyroidectomy medical

"and scarless Transoral Endoscopic Thyroidectomy. His participation in this"

A transoral endoscopic thyroidectomy is a minimally invasive surgery to remove part or all of the thyroid gland by inserting a tiny camera and instruments through small openings in the mouth instead of a neck incision. For investors, it matters because the technique can change demand for surgical tools, drive patient preference for scarless options, affect hospital procedure volumes and costs, and influence reimbursement and adoption curves for medical device and healthcare service providers.

AI-generated analysis. Not financial advice.

NEW YORK, Dec. 8, 2025 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a market leader in Microwave Ablation (MWA) technology, recently concluded an advanced MWA training session in New Orleans. This initiative reinforces the Company's commitment to accelerating the adoption of minimally invasive therapies through strategic physician education.

The specialized training program was led by Dr. Emad Kandil, Professor and Ellis Hanna Chair in Surgery at Tulane University School of Medicine. The program provided advanced training to Dr. Richard Harding, a distinguished surgeon and founder of Arizona Endocrine Surgery and the Thyroid Nodule Treatment Center in Phoenix.

Dr. Harding is widely recognized as a pioneer of interventional thyroidology in the Southwest. A former Commander in the U.S. Navy and Fellow of the American College of Surgeons (FACS), he was the first surgeon in Arizona to perform both thyroid Radiofrequency Ablation (RFA) and scarless Transoral Endoscopic Thyroidectomy. His participation in this program marks a key step in expanding patient access to non-surgical treatment options in the region.

The immersive itinerary included the observation of three live MWA procedures, allowing for a critical evaluation of the technology's clinical efficacy and procedural efficiency. Following a hands-on component, Dr. Harding and Dr. Kandil engaged in strategic discussions regarding the integration of MWA into Dr. Harding's practice to further enhance patient options in Arizona.

Upon completion, Dr. Harding was awarded a Certificate of Completion, signifying his proficiency in the MWA technology. This session highlights Baird Medical's ongoing mission to elevate global treatment standards by fostering knowledge exchange among top-tier medical professionals.

About Baird Medical

Baird Medical is a forward-thinking medical device company specializing in minimally invasive diagnostics and treatment. It is dedicated to the research and development of surgical robotic systems and innovative minimally invasive surgical instruments. Our mission is to enhance patient outcomes through precision technology and advanced diagnostic solutions. The company will foster strategic collaborations with leading academic institutions. Our vision extends beyond surgical assistance, aiming to develop intelligent systems that proactively guide diagnostic decisions and preventive healthcare strategies. As an FDA 510(k)-certified medical device company, Baird Medical's solutions have been used in over 30 prestigious hospitals and clinics across the United States, including Mayo Clinic, Tulane Medical Center, Columbia University Medical Center, UCSF Medical Center, Weill Cornell Medical Center, and The George Washington University Hospital. Baird Medical is also the market leader in China in thyroid microwave ablation devices and consumables. Meanwhile, the company's minimally invasive treatment products are gradually expanding their commercial presence in over 20 countries worldwide.

Forward-Looking Statements

This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Baird Medical's future financial or operating performance. In some cases, you can identify forward-looking statements by terminology such as "may", "could", "should", "expect", "intend", "might", "will", "estimate", "anticipate", "believe", "budget", "forecast", "intend", "plan", "potential", "predict", or "continue", or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Baird Medical does not undertake any duty to update these forward-looking statements.

Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors, including, without limitation: (1) the risk that Baird Medical may not be successful in expanding its business in China or the United States; (2) changes in general economic conditions; (3) regulatory conditions and developments; (4) changes in applicable laws or regulations; (5) the nature, cost and outcome of pending and future litigation and other legal proceedings instituted against Baird Medical or others; and (6) other risks and uncertainties from time to time described in the Registration Statement relating to the Business Combination and the transition report, including those listed under the sections titled "Risk Factors" therein, and in ExcelFin's other filings with the SEC. 

The foregoing list of factors is not exclusive. Additional information concerning certain of these, and other risk factors is contained in ExcelFin's most recent filings with the SEC and in the Registration Statement described above filed by Baird Medical in connection with its business combination with ExcelFin. All subsequent written and oral forward-looking statements concerning Baird Medical, the business combination described herein or other matters attributable to Baird Medical or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Baird Medical expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in their expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

Contact:
Eric Huang, PR Liaison
Baird Medical Investment Holdings Ltd.
Phone: +1 (888) 508-6228
Email: ir@bairdmed.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/baird-sponsored-microwave-ablation-training-enhances-thyroid-treatment-capabilities-for-leading-arizona-surgeon-302634879.html

SOURCE BDMD

FAQ

What did Baird Medical (BDMD) announce on December 8, 2025?

Baird Medical completed an advanced Microwave Ablation (MWA) training session led by Dr. Emad Kandil, training Dr. Richard Harding and awarding a Certificate of Completion.

Who participated in the BDMD-sponsored MWA training and where is the surgeon based?

Dr. Emad Kandil led the program and trained Dr. Richard Harding, a Phoenix-based surgeon and founder of Arizona Endocrine Surgery.

How many live procedures were observed during the BDMD MWA training on Dec. 8, 2025?

Participants observed three live MWA procedures as part of the immersive training itinerary.

What is the expected local impact of BDMD's MWA training for patients in Arizona?

The training aims to expand patient access to non‑surgical thyroid treatment options by integrating MWA into Dr. Harding’s Phoenix practice.

Did Dr. Richard Harding receive certification after the BDMD training?

Yes; Dr. Harding was awarded a Certificate of Completion signifying proficiency in the MWA technology.